Evidence map›Paper›PMID 36697775›Full record

ArticleCommunications chemistry2021

Diselenide crosslinks for enhanced and simplified oxidative protein folding.

Reem Mousa, Taghreed Hidmi, Sergei Pomyalov, Shifra Lansky, Lareen Khouri, Deborah E Shalev, Gil Shoham, Norman Metanis

Abstract read
In one paragraph

Article in Communications chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Effects of Selenocysteine Substitution on the Cyclotide Kalata B2.Chembiochem : a European journal of chemical biology · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Selenium in Peptide Chemistry.Molecules (Basel, Switzerland) · 2023
    Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Reem MousaInstitute of Chemistry, The Hebrew University of Jerusalem, Jerusalem, Israel.
Taghreed HidmiInstitute of Chemistry, The Hebrew University of Jerusalem, Jerusalem, Israel.ORCID http://orcid.org/0000-0001-6099-0518
Sergei PomyalovInstitute of Chemistry, The Hebrew University of Jerusalem, Jerusalem, Israel.ORCID http://orcid.org/0000-0002-2115-4477
Shifra LanskyInstitute of Chemistry, The Hebrew University of Jerusalem, Jerusalem, Israel.
Lareen KhouriInstitute of Chemistry, The Hebrew University of Jerusalem, Jerusalem, Israel.
Deborah E ShalevDepartment of Pharmaceutical Engineering, Azrieli College of Engineering Jerusalem and Wolfson Centre for Applied Structural Biology, The Hebrew University of Jerusalem, Jerusalem, Israel.
Gil ShohamInstitute of Chemistry, The Hebrew University of Jerusalem, Jerusalem, Israel. Gil2@mail.huji.ac.il.
Norman MetanisInstitute of Chemistry, The Hebrew University of Jerusalem, Jerusalem, Israel. Metanis@mail.huji.ac.il.

Funding

Israel Cancer Research Fund (Israel Cancer Research Fund, Inc.) Acceleration GrantIsrael Science Foundation (ISF) 1072/14Israel Science Foundation (ISF) 1905/15Israel Science Foundation (ISF) 783/18
6 · The paper itself

Abstract

The in vitro oxidative folding of proteins has been studied for over sixty years, providing critical insight into protein folding mechanisms. Hirudin, the most potent natural inhibitor of thrombin, is a 65-residue protein with three disulfide bonds, and is viewed as a folding model for a wide range of disulfide-rich proteins. Hirudin's folding pathway is notorious for its highly heterogeneous intermediates and scrambled isomers, limiting its folding rate and yield in vitro. Aiming to overcome these limitations, we undertake systematic investigation of diselenide bridges at native and non-native positions and investigate their effect on hirudin's folding, structure and activity. Our studies demonstrate that, regardless of the specific positions of these substitutions, the diselenide crosslinks enhanced the folding rate and yield of the corresponding hirudin analogues, while reducing the complexity and heterogeneity of the process. Moreover, crystal structure analysis confirms that the diselenide substitutions maintained the overall three-dimensional structure of the protein and left its function virtually unchanged. The choice of hirudin as a study model has implications beyond its specific folding mechanism, demonstrating the high potential of diselenide substitutions in the design, preparation and characterization of disulfide-rich proteins.

Identifiers

PMID36697775
PMCPMC9814483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.